TA Associates Management, L.P. through its funds Ta Xiii-B, L.P., Ta Xiii-A, L.P. and TA Investors XIII, L.P. made an offer to acquire Elos Medtech AB (publ) (OM:ELOS B) from a group of sellers for SEK 1.7 billion on June 11, 2021. The shareholders of Elos Medtech are offered SEK 215 in cash per share of series A and B in Elos Medtech. Should Elos Medtech, prior to the settlement of the tender offer, distribute dividends or in any other way distribute or transfer value to its shareholders, the consideration in the offer will be adjusted accordingly. The consideration payable in respect of the Offer is financed in full by a combination of funds available to EM Intressenter (fake company being made solely for the offer by TA Associates Management) by way of commitments from its owners and its closely related parties, and debt financing arranged or provided to EM Intressenter on terms customary for financing of public offers on the Swedish market. If EM Intressenter, whether in connection with the Offer or otherwise, acquires shares representing more than 90% of the total number of shares in Elos Medtech, EM Intressenter intends to commence compulsory redemption proceedings under the Swedish Companies Act (Sw.aktiebolagslagen (2005:551)) to acquire all remaining shares in Elos Medtech and to promote delisting of Elos Medtech's shares from Nasdaq Stockholm.

TA Associates' plans for the future business and general strategy do not currently include any material changes with regard to Elos Medtech's operational sites, its management and employees, including their terms of employment. Furthermore, there are no employees in EM Intressenter, implying that the offer will not entail any changes for the management and employees in EM Intressenter. The offer is conditional upon the offer being accepted to such extent that TA Associates Management becomes the owner of shares representing more than 80% of the total number of outstanding shares and more than 50% of the total number of outstanding votes in Elos Medtech and other conditions. The completion of the offer is not subject to any financing condition. Additionally, the transaction will not require any approvals from competition authorities or any other authorities. Svolder and the Nilsson family, with in total approximately 21.2% of the shares and 37.5% of the votes in Elos Medtech, have irrevocably undertaken to accept the Offer, irrespective of whether or not a higher competing offer is announced. The acceptance period for the Offer is expected to commence on or about June 14, 2021 and expire on or about July 5, 2021. At the end of the acceptance period on July 5, 2021, an aggregate 584,914 A-shares and 5,314,201 B-shares in Elos Medtech were tendered, corresponding to approximately 73.1% of the share capital and 62.1% of the voting rights in Elos Medtech. TA Associates waives the condition regarding a minimum level of acceptance in the offer. Furthermore, all other conditions for completion of the offer have been satisfied and accordingly, the offer is declared unconditional. Settlement will take place around July 14, 2021. To provide the remaining shareholders of Elos Medtech who have not tendered their shares time to accept the offer, the acceptance period will be extended until 14 July 2021, the settlement of which is expected to start around July 23, 2021.

Avanza Bank AB (publ) acted as financial advisor and Ola Sandersson, Fredrik Rydin, Erik Persson, Miikka Kujanpää, Carl Ivars, Arvid Weimers, Sidar Långhavet, Elias Olsson and Kristian Hugmark of Roschier Advokatbyrå Ab acted as legal advisors to TA Associates Management. Carnegie Investment Bank AB (publ) acted as financial advisor, Erik Sjöman and Wibeke Sorling of Vinge acted as legal advisors and Grant Thornton has been engaged as fairness opinion provider to Elos Medtech in connection to the offer.

TA Associates Management, L.P. through its funds Ta Xiii-B, L.P., Ta Xiii-A, L.P. and TA Investors XIII, L.P. completed the acquisition of 79.5% stake in Elos Medtech AB (publ) (OM:ELOS B) from a group of sellers for SEK 1.4 billion on July 14, 2021.